Science

Stephen Liu: Phase III Study of 1L Limertinib vs Gefitinib in NSCLC

Stephen Liu/LinkedIn

Jun 22, 2025, 12:13

Stephen Liu: Phase III Study of 1L Limertinib vs Gefitinib in NSCLC

Stephen Liu, Director of Thoracic Oncology and Associate Professor of Medicine at Georgetown University, shared a post on X:

“Phase III study of 1L limertinib (3G TKI) vs gefitinib in NSCLC.

Limertinib superior with PFS 20.7m vs 9.7m (HR 0.44), same rate of G3+ TRAEs. Good to have more agents but I do think the days of 1G TKI control arms have passed…”

Title: Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial

Authors: Yuankai Shi, Lin Wu, Yinghua Ji, Gongyan Chen, Baolan Li, Minghong Bi, Runxiang Yang, Liyun Miao, Guojun Zhang, Hongjun Gao, Longhua Sun, Mingjun Zhang, Shundong Cang, Meili Sun, Wenxiu Yao, Zhijie Pan, Jiuwei Cui, Yi Xiao, Qiming Wang

You can read the Full Article on The Lancet Respiratory Medicine

Stephen Liu: Phase III Study of 1L Limertinib vs Gefitinib in NSCLC

More posts featuring Stephen Liu.

Baolan Li cancer Cancer research Gefitinib Gongyan Chen Guojun Zhang Hongjun Gao Jiuwei Cui limertinib Lin Wu Liyun Miao Longhua Sun Meili Sun Minghong Bi Mingjun Zhang NSCLC OncoDaily Oncology Qiming Wang Runxiang Yang Shundong Cang The Lancet Respiratory Medicine Wenxiu Yao Yi Xiao Yinghua Ji Yuankai Shi Zhijie Pan

Cancer in Dogs: Common Types, Symptoms, Diagnosis, and Treatment

Cardio-Oncology in Focus: How Chemotherapy Can Harm Heart Health

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?